Becton Dickinson & Company
Research Becton Dickinson & Company (BDX) on Bullrun: valuation model: 45.6% overvalued, market cap USD 51.69B, P/E 57.2, dividend yield 2.0%. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerBDX
- ExchangeNYSE
- CountryUnited States
- SectorHealthcare
- IndustryMedical Instruments & Supplies
- CurrencyUSD
- Valuation signal45.6% overvalued
- Market capUSD 51.69B
- P/E57.2
- Dividend yield2.0%
- Financial periodQ2 2026
- RevenueUSD 4.98B
- Net incomeUSD 377.00M
- Free cash flowUSD 508.00M
- Gross margin46.5%
Valuation Snapshot
Bullrun's latest valuation model marks Becton Dickinson & Company as 45.6% overvalued; latest market cap is USD 51.69B; P/E is 57.2; dividend yield is 2.0%.
Peer valuation comparison
Latest P/E is 57.24x versus a Healthcare sector median of 24.46x (134.0% above).
Latest dividend yield is 1.99% versus a Healthcare sector median of 2.11% (5.7% below).
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | USD 21.84B | USD 1.68B | USD 2.67B | 45.4% | 5.82 | USD 567.00M | USD 19.18B | USD 25.39B |
| FY2024 | USD 20.18B | USD 1.71B | USD 3.12B | 45.2% | 5.86 | USD 1.72B | USD 20.11B | USD 25.89B |
| FY2023 | USD 19.37B | USD 1.48B | USD 2.12B | 42.2% | 4.94 | USD 1.42B | USD 15.88B | USD 25.80B |
| FY2022 | USD 18.87B | USD 1.78B | USD 1.50B | 44.9% | 5.88 | USD 1.01B | USD 16.07B | USD 25.28B |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-25 | USD 51.69B | 57.2 | 2.0% | 3.74 |
| 2025 | 2025-12-31 | USD 43.44B | 24.9 | 2.2% | 3.29 |
| 2024 | 2024-12-31 | USD 51.21B | 29.6 | 1.7% | 3.07 |
| 2023 | 2023-12-29 | USD 55.50B | 38.6 | 1.5% | 2.91 |
| 2022 | 2022-12-30 | USD 56.83B | 33.4 | 1.4% | 2.75 |
| 2021 | 2021-12-31 | USD 54.93B | 35.9 | 1.3% | 2.59 |
Dividend history
Latest trailing dividend snapshot: annual dividend/share 3.74 USD, yield 2.0%.
| Year | Dividends/share |
|---|---|
| FY2025 | 4.16 USD |
| FY2024 | 3.8 USD |
| FY2023 | 3.64 USD |
| FY2022 | 3.48 USD |
About Becton Dickinson & Company
Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. It operates through Medical Essentials, Connected Care, BioPharma Systems, Interventional and Life Sciences segments.
Related stock research
Other Healthcare stocks
Frequently asked questions
Is Becton Dickinson & Company overvalued or undervalued?
Bullrun's valuation model currently marks Becton Dickinson & Company as 45.6% overvalued.
What is Becton Dickinson & Company's market cap?
Becton Dickinson & Company's market capitalization is USD 51.69B.
What is Becton Dickinson & Company's P/E ratio?
Becton Dickinson & Company's price-to-earnings (P/E) ratio is 57.2.
Does Becton Dickinson & Company pay a dividend?
Becton Dickinson & Company has a dividend yield of 2.0%.
What does Becton Dickinson & Company do?
Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. It operates through Medical Essentials, Connected Care, BioPharma Systems, Interventional and Life Sciences segments.